Research on Crucial Role of PET-Guided Biopsy in Initial Breast Cancer Diagnosis and Presurgical Planning Published in The Breast Journal

Data Demonstrate Percentage of Breast Cancer Biopsies Seen Only on PEM Imaging

SAN DIEGO, March 31, 2011 - The Breast Journal recently published original prospective data
confirming the technical validity of image-guided needle biopsy of suspicious
breast cancer lesions using Positron Emission Mammography (PEM)-guidance. The
study, which used the Naviscan high-resolution breast PET scanner, otherwise
known as a PEM scanner, marks the first time PET imaging alone has been able
to target regions in the breast with abnormal FDG uptake and guide the
extraction for histopathologic analysis.

The main objective of the study was to confirm successful targeting and
lesion sampling. A second objective was to confirm the safety and patient
comfort during the procedure. Six physicians, using three different
commercially available vacuum-assisted biopsy tools, conducted this study at
five sites. A total of 24 PEM-guided biopsies were completed with 100%
success.

The most important advantage of PEM-guided biopsy is the ability to
target and biopsy lesions that are difficult to see on other imaging tools
giving patients and physicians another option in the fight against breast
cancer. "I am so thankful that I was able to have this procedure," stated
Sally Ryser, a patient from Boca Raton, Florida who participated in the
study. "The type of cancer that I had is called triple negative and
apparently is a very aggressive form of cancer. Had I not had the PEM scan
and the PEM biopsy, who knows what my prognosis would have been had the
cancer not been detected. I truly feel that these innovative PEM procedures
most likely saved my life."

"PEM-guided biopsy is quite elegant and confers several advantages over
MRI-guided biopsy," stated Dr. Wendie Berg, a co-author of the paper. "We can
easily image the breast after sampling to assure removal of the target, and
resample at the same setting if needed. With PEM, we also have the ability to
directly image the specimens, which both further confirms successful sampling
and allows us to direct the pathologist's attention to the 'hot' specimens."

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution
PET scanners intended to provide organ-specific molecular imaging and guide
radiological and surgical procedures. The Naviscan PEM scanner is currently
installed and available in breast and imaging centers throughout the U.S. and
other parts of the world. The Company is headquartered in San Diego,
California and is the first to obtain FDA-clearance for a high-resolution PET
scanner designed to image small body parts and for breast biopsy image
guidance. For more information, call +1-858-587-3641 or visit
www.naviscan.com.

Guillaume Bailliard, EVP, Marketing of Naviscan, Inc., +1-858-332-0941, gbailliard at naviscan.com; or Joleen Schultz, Naviscan Marketing Communications, Mentus Life Science, +1-858-455-5500, jschultz at naviscan.com